Liverty™ TIPS Stent Graft Receives CE Mark, Expanding Treatment Options
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy BDX?
Source: PRnewswire
- Innovative Medical Device: BD announced that the Liverty™ TIPS Stent Graft has received CE marking, aimed at improving treatment options for patients with cirrhosis, particularly for complex conditions related to portal hypertension, marking the company's latest advancement in interventional therapies.
- Clinical Study Data: Safety and efficacy data for the Liverty™ TIPS Stent Graft will be presented for the first time at the Society of Interventional Radiology annual meeting on April 12, 2026, which is expected to provide crucial clinical evidence for physicians and promote widespread adoption of the device.
- Market Demand Response: With approximately 58 million people affected by cirrhosis globally, the launch of the Liverty™ TIPS Stent Graft not only addresses the urgent need for safe, effective, and adaptable treatment options but also has the potential to significantly improve long-term health outcomes for patients.
- Personalized Treatment Solutions: The stent features an adjustable diameter of 6 to 10 mm and a variety of length options, allowing physicians to tailor treatments based on individual patient physiology, thereby enhancing the safety and effectiveness of the interventions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BDX
Wall Street analysts forecast BDX stock price to rise
11 Analyst Rating
5 Buy
6 Hold
0 Sell
Moderate Buy
Current: 155.460
Low
157.00
Averages
192.64
High
232.00
Current: 155.460
Low
157.00
Averages
192.64
High
232.00
About BDX
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. It operates through four segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems and BD Interventional. BD Medical Essentials segment includes medication delivery solutions and specimen management. BD Connected Care segment includes medication management solutions and advanced patient monitoring. BD Interventional segment includes urology and critical care, peripheral intervention and surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
TSMC Reports 35% Revenue Growth in Q1
- TSMC's Strong Performance: TSMC reported a 35% year-over-year revenue increase in Q1, with March alone seeing a 45% surge, indicating robust demand in the semiconductor market that could help Nvidia's stock break free and join the ranks of memory stocks.
- Intel Price Target Raised: Melius Research raised Intel's price target from $58 to $75 while maintaining a buy rating, reflecting optimism about its partnerships with Elon Musk's Terafab project and Google, with CEO Lip-Bu Tan's leadership being widely acknowledged.
- UBS Downgrades ServiceNow: UBS downgraded ServiceNow from buy to hold, citing weakened confidence in its ability to withstand AI disruption, despite the stock already being down 41% year-to-date, indicating a significant shift in analyst sentiment.
- Southern Company Price Target Increased: Citi raised Southern Company's price target from $107 to $114, as analysts see growth potential amid the surge in demand for electricity driven by AI data centers, maintaining a buy rating and reflecting optimism in the utility sector.
See More
Liverty™ TIPS Stent Graft Receives CE Mark, Expanding Treatment Options
- Innovative Medical Device: BD announced that the Liverty™ TIPS Stent Graft has received CE marking, aimed at improving treatment options for patients with cirrhosis, particularly for complex conditions related to portal hypertension, marking the company's latest advancement in interventional therapies.
- Clinical Study Data: Safety and efficacy data for the Liverty™ TIPS Stent Graft will be presented for the first time at the Society of Interventional Radiology annual meeting on April 12, 2026, which is expected to provide crucial clinical evidence for physicians and promote widespread adoption of the device.
- Market Demand Response: With approximately 58 million people affected by cirrhosis globally, the launch of the Liverty™ TIPS Stent Graft not only addresses the urgent need for safe, effective, and adaptable treatment options but also has the potential to significantly improve long-term health outcomes for patients.
- Personalized Treatment Solutions: The stent features an adjustable diameter of 6 to 10 mm and a variety of length options, allowing physicians to tailor treatments based on individual patient physiology, thereby enhancing the safety and effectiveness of the interventions.
See More
Becton, Dickinson: A Quality Stock in a Market Crash
- Market Crash Anticipation: With the Nasdaq Composite recently entering correction territory, investor fears of a market crash are rising; while a crash is not guaranteed, it could present a prime opportunity for stock investment.
- Core Business Focus: Becton, Dickinson has spun off its diabetes care and biosciences units to concentrate on its core medtech business, which is expected to enhance sales growth and strengthen its competitive position in the market.
- Attractive Valuation: Currently, Becton, Dickinson's forward P/E stands at 12.3, significantly lower than the healthcare industry average of 16.8, suggesting that its shares could become even cheaper in a market crash, drawing more investor interest.
- Dividend Advantage: With 54 consecutive years of dividend increases, Becton, Dickinson is classified as a
See More
Market Fears Rise, Healthcare Stocks as Top Investment Picks
- Market Uncertainty: With the Nasdaq Composite recently entering correction territory, investor fears of an impending bear market have intensified; while no clear market crash is guaranteed, escalating trade wars and geopolitical tensions contribute to this anxiety.
- Becton’s Market Position: Becton, Dickinson & Company maintains a strong leadership position in the medical device sector, with over 90% of its revenue derived from everyday consumables, providing a stable sales source despite facing recalls and tariff threats due to its trusted brand reputation.
- Business Restructuring and Growth Potential: By spinning off its diabetes care segment, Becton, Dickinson is focusing on its core medtech business, which is expected to enhance sales growth; its current forward P/E of 12.3 is attractive compared to the healthcare industry's average of 16.8, indicating strong investment potential in a market crash.
- Intuitive Surgical’s Long-Term Prospects: Despite facing competition and tariff pressures, Intuitive Surgical's leading position in the robotic-assisted surgery market, with over 11,000 installed da Vinci systems, ensures significant recurring revenue, making it a compelling buy opportunity during a market downturn.
See More
BD PureWick® Urine Collection System Enhances Women's Sleep Quality
- Clinical Study Findings: A four-week randomized trial involving 165 women revealed that the BD PureWick® Flex Urine Collection System significantly improved sleep quality, demonstrating its effectiveness and comfort in non-invasive urinary management.
- Enhanced User Experience: Participants highlighted the system's ease of use and non-invasive design, allowing them to stay dry overnight and reducing the need for frequent bathroom trips, thereby lowering fall risks, particularly for women aged 65 and older.
- Quality of Life Improvement: The study indicated that women using the system experienced significant enhancements in comfort and confidence, suggesting that the product not only alleviates the daily burden of incontinence but also promotes independence and dignity among users.
- Broad Market Potential: BD's research showcases its innovative capabilities in the non-invasive urinary management device sector, which is expected to drive widespread adoption of the PureWick® system in home care markets, addressing the growing demand.
See More
BD Launches Liverty™ TIPS Stent to Expand Liver Disease Treatment Options
- CE Certification Progress: BD has applied for CE certification for the Liverty™ TIPS Stent, aiming to innovatively advance portal hypertension treatment across the EU, which is expected to significantly enhance treatment options for cirrhosis patients and strengthen the company's competitiveness in the medical device market.
- Clinical Study Data: Safety and efficacy data for the Liverty™ TIPS Stent will be presented for the first time at the Society of Interventional Radiology annual meeting on April 12, 2026, marking BD's latest advancement in interventional therapies for complex liver diseases and potentially attracting more healthcare institutions' interest.
- Personalized Treatment Design: The stent features an adjustable diameter (6 to 10 mm) and a variety of length options, designed to provide personalized treatment plans based on patients' physiological characteristics, thereby improving treatment safety and effectiveness while meeting market demand for flexible treatment solutions.
- Global Health Challenge: According to the Global Burden of Disease study, approximately 58 million people are affected by liver cirrhosis, and the launch of the Liverty™ TIPS Stent will help alleviate severe complications caused by portal hypertension, further solidifying BD's leadership position in the global healthcare sector.
See More
TSMC Reports 35% Revenue Growth in Q1
- TSMC's Strong Performance: TSMC reported a 35% year-over-year revenue increase in Q1, with March alone seeing a 45% surge, indicating robust demand in the semiconductor market that could help Nvidia's stock break free and join the ranks of memory stocks.
- Intel Price Target Raised: Melius Research raised Intel's price target from $58 to $75 while maintaining a buy rating, reflecting optimism about its partnerships with Elon Musk's Terafab project and Google, with CEO Lip-Bu Tan's leadership being widely acknowledged.
- UBS Downgrades ServiceNow: UBS downgraded ServiceNow from buy to hold, citing weakened confidence in its ability to withstand AI disruption, despite the stock already being down 41% year-to-date, indicating a significant shift in analyst sentiment.
- Southern Company Price Target Increased: Citi raised Southern Company's price target from $107 to $114, as analysts see growth potential amid the surge in demand for electricity driven by AI data centers, maintaining a buy rating and reflecting optimism in the utility sector.
See More
Liverty™ TIPS Stent Graft Receives CE Mark, Expanding Treatment Options
- Innovative Medical Device: BD announced that the Liverty™ TIPS Stent Graft has received CE marking, aimed at improving treatment options for patients with cirrhosis, particularly for complex conditions related to portal hypertension, marking the company's latest advancement in interventional therapies.
- Clinical Study Data: Safety and efficacy data for the Liverty™ TIPS Stent Graft will be presented for the first time at the Society of Interventional Radiology annual meeting on April 12, 2026, which is expected to provide crucial clinical evidence for physicians and promote widespread adoption of the device.
- Market Demand Response: With approximately 58 million people affected by cirrhosis globally, the launch of the Liverty™ TIPS Stent Graft not only addresses the urgent need for safe, effective, and adaptable treatment options but also has the potential to significantly improve long-term health outcomes for patients.
- Personalized Treatment Solutions: The stent features an adjustable diameter of 6 to 10 mm and a variety of length options, allowing physicians to tailor treatments based on individual patient physiology, thereby enhancing the safety and effectiveness of the interventions.
See More
Becton, Dickinson: A Quality Stock in a Market Crash
- Market Crash Anticipation: With the Nasdaq Composite recently entering correction territory, investor fears of a market crash are rising; while a crash is not guaranteed, it could present a prime opportunity for stock investment.
- Core Business Focus: Becton, Dickinson has spun off its diabetes care and biosciences units to concentrate on its core medtech business, which is expected to enhance sales growth and strengthen its competitive position in the market.
- Attractive Valuation: Currently, Becton, Dickinson's forward P/E stands at 12.3, significantly lower than the healthcare industry average of 16.8, suggesting that its shares could become even cheaper in a market crash, drawing more investor interest.
- Dividend Advantage: With 54 consecutive years of dividend increases, Becton, Dickinson is classified as a
See More
Market Fears Rise, Healthcare Stocks as Top Investment Picks
- Market Uncertainty: With the Nasdaq Composite recently entering correction territory, investor fears of an impending bear market have intensified; while no clear market crash is guaranteed, escalating trade wars and geopolitical tensions contribute to this anxiety.
- Becton’s Market Position: Becton, Dickinson & Company maintains a strong leadership position in the medical device sector, with over 90% of its revenue derived from everyday consumables, providing a stable sales source despite facing recalls and tariff threats due to its trusted brand reputation.
- Business Restructuring and Growth Potential: By spinning off its diabetes care segment, Becton, Dickinson is focusing on its core medtech business, which is expected to enhance sales growth; its current forward P/E of 12.3 is attractive compared to the healthcare industry's average of 16.8, indicating strong investment potential in a market crash.
- Intuitive Surgical’s Long-Term Prospects: Despite facing competition and tariff pressures, Intuitive Surgical's leading position in the robotic-assisted surgery market, with over 11,000 installed da Vinci systems, ensures significant recurring revenue, making it a compelling buy opportunity during a market downturn.
See More
BD PureWick® Urine Collection System Enhances Women's Sleep Quality
- Clinical Study Findings: A four-week randomized trial involving 165 women revealed that the BD PureWick® Flex Urine Collection System significantly improved sleep quality, demonstrating its effectiveness and comfort in non-invasive urinary management.
- Enhanced User Experience: Participants highlighted the system's ease of use and non-invasive design, allowing them to stay dry overnight and reducing the need for frequent bathroom trips, thereby lowering fall risks, particularly for women aged 65 and older.
- Quality of Life Improvement: The study indicated that women using the system experienced significant enhancements in comfort and confidence, suggesting that the product not only alleviates the daily burden of incontinence but also promotes independence and dignity among users.
- Broad Market Potential: BD's research showcases its innovative capabilities in the non-invasive urinary management device sector, which is expected to drive widespread adoption of the PureWick® system in home care markets, addressing the growing demand.
See More
BD Launches Liverty™ TIPS Stent to Expand Liver Disease Treatment Options
- CE Certification Progress: BD has applied for CE certification for the Liverty™ TIPS Stent, aiming to innovatively advance portal hypertension treatment across the EU, which is expected to significantly enhance treatment options for cirrhosis patients and strengthen the company's competitiveness in the medical device market.
- Clinical Study Data: Safety and efficacy data for the Liverty™ TIPS Stent will be presented for the first time at the Society of Interventional Radiology annual meeting on April 12, 2026, marking BD's latest advancement in interventional therapies for complex liver diseases and potentially attracting more healthcare institutions' interest.
- Personalized Treatment Design: The stent features an adjustable diameter (6 to 10 mm) and a variety of length options, designed to provide personalized treatment plans based on patients' physiological characteristics, thereby improving treatment safety and effectiveness while meeting market demand for flexible treatment solutions.
- Global Health Challenge: According to the Global Burden of Disease study, approximately 58 million people are affected by liver cirrhosis, and the launch of the Liverty™ TIPS Stent will help alleviate severe complications caused by portal hypertension, further solidifying BD's leadership position in the global healthcare sector.
See More
